When Will ImmuCell Corporation (NASDAQ:ICCC) Report Its Unaudited Quarterly Results?

Sonal Goyal

09 November 2026 04:25 PM AEDT

When Will ImmuCell Corporation (NASDAQ:ICCC) Report Its Unaudited Quarterly Results?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Unaudited results for the quarter ended September 30, 2026 are scheduled after market close on November 12, 2026.
A conference call and live webcast will take place on November 13, 2026 at 9:00 AM ET.
The company expects no change to preliminary sales results disclosed on October 12, 2026.
The Form 10-Q is expected to be filed on November 12, 2026 after the market closes.

ImmuCell Corporation (NASDAQ:ICCC) said it expects to report unaudited financial results for the quarter ended September 30, 2026 after the market closes on Thursday, November 12, 2026. The Portland, Maine company develops, manufactures and markets animal health Biologics designed to improve calf health and productivity.

Results Release and Conference Call

The company plans to host a conference call and webcast on November 13, 2026 at 9:00 AM Eastern Time to review the unaudited results. A live webcast will feature a set of presentation slides, which will be posted in the Investors section of the company's website after the event.

The company's investor website also hosts its press releases and other company information.

Sales and Quarterly Filing Timing

ImmuCell said it anticipates no change to the preliminary sales results for the quarter ended September 30, 2026, which it had disclosed on October 12, 2026. The November announcement is therefore expected to provide the full unaudited statements for the period, following the earlier preliminary sales update. The company also expects to file its Quarterly Report on Form 10-Q on November 12, 2026, after the market closes.

The sequence of events is useful for shareholders and other readers. The Earnings release, the Form 10-Q and the conference call are scheduled on consecutive days, so the company's full quarterly disclosure will be concentrated in a short window in mid-November.

About the Company and Its Products

ImmuCell operates in the calf health market and develops, manufactures and commercializes its First Defense line of products. These products are described by the company as providing immediate immunity through colostrum-derived, orally delivered antibodies against the main viral and bacterial causes of scours. Scours, also called neonatal calf diarrhea, is one of the most prevalent and deadly diseases in newborn calves worldwide, according to the company's description.

The company's Business is therefore tied to livestock health and productivity, a market that depends on dairy and beef production conditions.

Preliminary sales results for the quarter were disclosed on October 12, 2026. Companies often share preliminary figures ahead of full results to give investors an early indication of performance. ImmuCell's statement that it anticipates no change to those sales results means the figures in the forthcoming release should match the earlier disclosure, so readers tracking the sales trend can rely on the October figures while waiting for the full statements.

The timetable covers the results release, the call and the Form 10-Q within a single week, which concentrates the quarterly disclosure into a short window.

The company's announcement includes a set of practical details for investors, including the conference line information and the webcast arrangements. Investors who want to review the company's slides can access them through the Investors section of its website, and the replay access code remains active for about one week after the call. These timing details make clear that the company intends to keep its investor materials available for a period after the call.

The timetable also shows how the company's reporting cycle is organized. The earnings release, the conference call, the replay and the Form 10-Q are arranged so that the company's numbers are available in one sequence. Readers who follow calf health companies will be able to compare ImmuCell's figures with the October sales disclosure once the full statements are published.

Final Word

ImmuCell's announcement sets out the timing for its third-quarter 2026 reporting, with the results release on November 12, a call on November 13 and the 10-Q filed in the same week. The company has said that preliminary sales figures for the quarter will not change. Full results, including profitability, cash position and operating costs, will be available once the company publishes its unaudited statements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.